ZBB Considered Useless By NCI Staff (Privately)’ New Approach Groups Program Into Four Categories
In Brief: Upton Okays Laetrile Clinical Trials, To Seek Protocols From Clinicians For IND Request
Regulatory Agencies Get Data For Action Against One Of World’s Most Widely Used Carcinogens
Change In Method Of Counting Cancer Incidence Results In More Attributed To Work Hazards
IG Report Clears Shubik Of Conflict Of Interest Change


Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
At the time, USPSTF was better equipped to do the job. Is it still?









